drugset
drugset / Trial / NCT01215799

Study of Bafetinib (INNO-406) as Treatment for Patients With Hormone-Refractory Prostate Cancer

NCT01215799 ↗

Phase 2 Completed 23 enrolled CytRx
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase II open-label study evaluating the preliminary efficacy and safety of bafetinib administered as 240 mg orally twice daily in subjects with Hormone Refractory Prostate Cancer.

Timeline

Start
2010-08
Primary completion
2011-09
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Bafetinib Small molecule 240 mg Oral

Indications

hormone-resistant prostate carcinoma